MTOR and breast carcinoma: To the best of our knowledge, this present preclinical study is the first to show that neratinib can potentially induce TGI in both HER2+ breast cancer and TNBC when co-treated with inhibitors of the PI3K/Akt-mTOR or MAPK pathway.